NICE Recommends Subcutaneous Treatment Option Tepkinly[®]▼(epcoritamab) for Eligible* Adults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy
· For the first time, adults with diffuse large B-cell lymphoma (DLBCL), whose cancer has returned or not responded to at least two prior treatments, only if they have previously had polatuzumab vedotin or it is contraindicated or not tolerated, will have access to a subcutaneous bispecific treatment option administered as an injection under the skin[1,2] · Epcoritamab is part of a new class of therapies called bispecific antibodies. Bispecific antibodies help the body’s immune system to attack and destroy cancerous cells[3] · DLBCL is an aggressive blood cancer, with nearly 5,500